Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | AKT2 | P31751 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.34 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158899 | 0.87 | JAK2 (0.37) | AKT1JAK2JAK3AKT2GSK3B | |
| SCHEMBL473319 | 0.79 | JAK2 (0.37) | AKT1JAK2JAK3KITCHIT1 | |
| SCHEMBL10157823 | 0.76 | AKT2 (0.42) | AKT1AKT2GSK3BKCNH2RPS6KB1 | |
| SCHEMBL473436 | 0.75 | RPS6KB1 (0.37) | AKT1JAK2JAK3AKT2GSK3B | |
| SCHEMBL473317 | 0.75 | CHRM4 (0.41) | AKT1JAK2JAK3AKT2GSK3B | |
| SCHEMBL15252736 | 0.74 | CHIT1 (0.44) | AKT1JAK2JAK3AKT2GSK3B | |
| SCHEMBL10158559 | 0.73 | AKT1 (0.44) | AKT1AKT2GSK3BKCNH2RPS6KB1 | |
| SCHEMBL473346 | 0.73 | CHRM4 (0.44) | AKT1JAK2JAK3AKT2GSK3B | |
| SCHEMBL10157820 | 0.73 | AKT2 (0.40) | AKT1AKT2GSK3BRPS6KB1 | |
| SCHEMBL15252826 | 0.73 | CHIT1 (0.43) | AKT1JAK2JAK3AKT2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848719-B1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2012-02-01 | — | — | EP | claimed |